Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Transcript

Why It Matters

The rapid revenue surge and emerging profitability position Legend as the leading commercial CAR‑T player, while its scalable manufacturing and strong pipeline promise sustained growth and a multi‑billion‑dollar market opportunity.

Key Takeaways

• CARVYKTI sales hit $555M, 66% YoY growth.
• Manufacturing capacity now 10,000 doses with 97% success.
• Adjusted net income turned positive, operating loss cut 75%.
• J&J partnership targets >$5B peak annual sales.
• Pipeline includes in vivo CAR‑T and allogeneic programs.

Pulse Analysis

Legend Biotech’s Q1 results underscore a transformative shift from a cash‑burning biotech to a revenue‑generating enterprise. Net trade sales of its CARVYKTI therapy surged to $555 million, outpacing the broader cell‑therapy market and delivering a 64% jump in total revenue. The company’s gross margin stability at 61% and a dramatic reduction in operating loss reflect disciplined cost management, while a near‑$1 billion cash reserve provides ample runway for strategic investments. This financial momentum not only validates the commercial viability of CAR‑T platforms but also signals to investors that the firm can sustain growth without compromising fiscal health.

Beyond the balance sheet, Legend’s manufacturing and clinical milestones reinforce its market leadership. The firm now operates a global production network capable of 10,000 annual doses, achieving a 97% success rate that rivals the industry’s best. Clinical data presented at ASH and Tandem highlighted a median progression‑free survival of 50.4 months in heavily pre‑treated patients, establishing a new benchmark for BCMA‑targeted therapies. Early‑line adoption is accelerating, with 65% of patients receiving CARVYKTI in second‑through‑fourth‑line settings, and the therapy is now available in 14 countries, treating over 10,000 patients worldwide.

Looking ahead, Legend’s partnership with Johnson & Johnson aims to scale CARVYKTI to a $5 billion peak sales horizon, while capacity expansion plans target up to 20,000 doses annually to meet rising demand. The pipeline, featuring in‑vivo CAR‑T candidates and allogeneic gamma‑delta CAR‑T programs, is slated for 1‑2 U.S. IND filings by year‑end, positioning the company for diversified growth beyond multiple myeloma. With a clear path to company‑wide profitability in 2026, robust cash resources, and a disciplined expense strategy, Legend Biotech is poised to capture a sizable share of the under‑penetrated BCMA market and drive long‑term shareholder value.